Evidence of a role for RANKL in the development of myeloma bone disease

被引:20
作者
De Leenheer, E
Mueller, GS
Vanderkerken, K
Croucher, PI
机构
[1] Univ Sheffield, Sch Med, Bone Biol Grp, Div Clin Sci, Sheffield S10 2RX, S Yorkshire, England
[2] Univ Oxford, Botnar Res Ctr, Nuffield Dept Orthopaed Surg, Oxford, England
[3] Free Univ Brussels, Dept Hematol & Immunol, Brussels, Belgium
关键词
D O I
10.1016/j.coph.2004.03.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple myeloma is associated with the development of a devastating bone disease mediated by increased osteoclastic activity. The ligand for receptor activator of nuclear factor-kappaB (RANKL) plays a critical role in normal osteoclast biology and is abnormally regulated in myeloma. Targeting this system with recombinant decoy receptor, osteoprotegerin, or soluble forms of the receptor activator of nuclear factor-kappaB is able to prevent myeloma bone disease in pre-clinical models. Intriguingly, inhibiting osteoclast formation and bone resorption, and altering the bone marrow microenvironment, results in an indirect anti-myeloma effect.
引用
收藏
页码:340 / 346
页数:7
相关论文
共 62 条
[1]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[2]   Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin [J].
Ashcroft, AJ ;
Cruickshank, SM ;
Croucher, PL ;
Perry, MJ ;
Rollinson, S ;
Lippitt, JM ;
Child, JA ;
Dunstan, C ;
Felsburg, PJ ;
Morgan, GJ ;
Carding, SR .
IMMUNITY, 2003, 19 (06) :849-861
[3]   RECRUITMENT OF NEW OSTEOBLASTS AND OSTEOCLASTS IS THE EARLIEST CRITICAL EVENT IN THE PATHOGENESIS OF HUMAN MULTIPLE-MYELOMA [J].
BATAILLE, R ;
CHAPPARD, D ;
MARCELLI, C ;
DESSAUW, P ;
BALDET, P ;
SANY, J ;
ALEXANDRE, C .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (01) :62-66
[4]   A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].
Body, JJ ;
Greipp, P ;
Coleman, RE ;
Facon, T ;
Geurs, F ;
Fermand, JP ;
Harousseau, JL ;
Lipton, A ;
Mariette, X ;
Williams, CD ;
Nakanishi, A ;
Holloway, D ;
Martin, SW ;
Dunstan, CR ;
Bekker, PJ .
CANCER, 2003, 97 (03) :887-892
[5]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[6]   Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease [J].
Choi, SJ ;
Oba, Y ;
Gazitt, Y ;
Alsina, M ;
Cruz, J ;
Anderson, J ;
Roodman, GD .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (12) :1833-1841
[7]  
Choi SJ, 2000, BLOOD, V96, P671
[8]   Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis [J].
Collin-Osdoby, P ;
Rothe, L ;
Anderson, F ;
Nelson, M ;
Maloney, W ;
Osdoby, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (23) :20659-20672
[9]   Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease [J].
Croucher, PI ;
Shipman, CM ;
Van Camp, B ;
Vanderkerken, K .
CANCER, 2003, 97 (03) :818-824
[10]   Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival [J].
Croucher, PI ;
De Raeve, H ;
Perry, MJ ;
Hijzen, A ;
Shipman, CM ;
Lippitt, J ;
Green, J ;
Van Marck, E ;
Van Camp, B ;
Vanderkerken, K .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (03) :482-492